Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.615 USD | -0.23% | -3.64% | -5.50% |
May. 17 | HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $18 From $21, Maintains Buy Rating | MT |
Apr. 02 | HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.50% | 18.67M | |
+37.89% | 705B | |
+32.82% | 583B | |
-3.64% | 364B | |
+19.86% | 332B | |
+4.99% | 291B | |
+16.64% | 238B | |
-4.13% | 210B | |
+10.63% | 209B | |
+8.89% | 169B |
- Stock Market
- Equities
- KALA Stock
- News KALA BIO, Inc.
- Wedbush Adjusts Kala Pharmaceuticals' Price Target to $3 From $6, Keeps Outperform Rating